Bevespi Aerosphere

Drooling, peripheral muscarinic effects, cardiac vagal inhibitory reflexes + 16 more

Treatment

20 Active Studies for Bevespi Aerosphere

Treatment for

Drooling

What is Bevespi Aerosphere

Glycopyrronium

The Generic name of this drug

Treatment Summary

Formoterol is an inhalable medication used to treat COPD and asthma that was approved for use in the United States in 2001. It helps to open airways in the lungs, allowing for easier breathing. Formoterol is especially useful because it takes effect quickly (2-3 minutes) and lasts for 12 hours. It is available as a single-entity product or in combination with other medications such as inhaled corticosteroids and long-acting muscarinic antagonists.

Robinul

is the brand name

image of different drug pills on a surface

Bevespi Aerosphere Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Robinul

Glycopyrronium

1961

294

Effectiveness

How Bevespi Aerosphere Affects Patients

Formoterol is a medication that helps open up the airways in the lungs, allowing for easier breathing. It begins to work within two to three minutes and can last up to twelve hours. It should never be taken without an inhaled corticosteroid as it is linked to an increased risk of asthma-related death.

How Bevespi Aerosphere works in the body

Formoterol is a medication that targets beta-2 receptors, which are found mostly in the lungs. This helps it to relax the airways and reduce inflammation, making it useful in treating conditions like asthma and COPD. On a molecular level, formoterol activates an enzyme that helps to convert energy into a form that relaxes the lungs and reduces inflammation.

When to interrupt dosage

The suggested measure of Bevespi Aerosphere is contingent upon the diagnosed issue, including Bronchial Asthma, Bronchoconstriction and Asthma. The quantity of dosage fluctuates depending on the administration system (e.g. Solution - Respiratory (inhalation) or Aerosol) noted in the table below.

Condition

Dosage

Administration

Drooling

, 1.0 mg, 2.0 mg, 0.2 mg/mL, 1.5 mg, 0.05 mg, 0.044 mg, 0.32 mg/mL, 1.0 mg/mL, 0.009 mg, 0.4 mg/mL, 0.0156 mg, 0.025 mg/mL, 0.024 mg/mg, 0.5 mg/mL, 0.0072 mg, 0.043 mg, 0.046 mg, 0.0083 mg/pump actuation, 0.0082 mg/pump actuation, 1.7 mg

, Oral, Tablet - Oral, Tablet, Intramuscular; Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection, solution, Injection, solution - Intravenous, Intravenous, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Respiratory (inhalation), Capsule, Capsule - Respiratory (inhalation), Solution, Solution - Oral, Liquid - Oral, Aerosol, metered, Aerosol, metered - Respiratory (inhalation), Solution - Respiratory (inhalation), Solution - Intramuscular; Intravenous, Cloth - Topical, Cloth, Topical, Injection, solution - Intramuscular; Intravitreal, Intramuscular; Intravitreal, Aerosol - Respiratory (inhalation), Aerosol, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating

Increased upper airway secretion

Induction of anesthesia therapy

Choking

Bronchitis, Chronic

Peptic Ulcer

General Surgery

Cerebral Palsy

Hyperhidrosis disorder

Oral cavity

Anticholinergic Syndrome

Reflex, Trigeminocardiac

Chronic Obstructive Pulmonary Disease

peripheral muscarinic effects

cardiac vagal inhibitory reflexes

Bodily secretions

Emphysema

Neurological Conditions

Warnings

Bevespi Aerosphere Contraindications

Condition

Risk Level

Notes

Ulcerative Colitis

Do Not Combine

Uterine Inertia

Do Not Combine

Ulcerative Colitis

Do Not Combine

Myasthenia Gravis

Do Not Combine

Arterial Occlusive Diseases

Do Not Combine

Cardiovascular Physiological Phenomena

Do Not Combine

Pulse Frequency

Do Not Combine

Therapeutic procedure

Do Not Combine

Intestinal Pseudo-Obstruction

Do Not Combine

Open-angle glaucoma

Do Not Combine

Uropathy Obstructive

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Glycopyrronium may interact with Pulse Frequency

There are 20 known major drug interactions with Bevespi Aerosphere.

Common Bevespi Aerosphere Drug Interactions

Drug Name

Risk Level

Description

Aclidinium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Aclidinium.

Cimetropium

Major

The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Cimetropium.

Eluxadoline

Major

The risk or severity of constipation can be increased when Glycopyrronium is combined with Eluxadoline.

Macimorelin

Major

The therapeutic efficacy of Macimorelin can be decreased when used in combination with Glycopyrronium.

Secretin human

Major

The therapeutic efficacy of Secretin human can be decreased when used in combination with Glycopyrronium.

Bevespi Aerosphere Toxicity & Overdose Risk

The lowest toxic dose of formoterol in rats is 3130mg/kg. Symptoms of overdose may include chest pain, high or low blood pressure, rapid heartbeat, anxiety, headache, trembling, seizures, and dry mouth. Laboratory tests may also show low levels of potassium, high blood sugar, and acidosis in the blood. Treatment for overdosing on formoterol should involve supportive care, with a focus on monitoring the heart. If necessary, a medication that blocks increased adrenaline may be used.

image of a doctor in a lab doing drug, clinical research

Bevespi Aerosphere Novel Uses: Which Conditions Have a Clinical Trial Featuring Bevespi Aerosphere?

251 active clinical trials are currently being conducted to evaluate the potential of Bevespi Aerosphere to alleviate symptoms of Chronic Obstructive Pulmonary Disease (COPD), Moderate to Severe COPD and Chronic Obstructive Airway Disease.

Condition

Clinical Trials

Trial Phases

Chronic Obstructive Pulmonary Disease

77 Actively Recruiting

Phase 3, Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 4

Choking

4 Actively Recruiting

Not Applicable

General Surgery

2 Actively Recruiting

Not Applicable

Hyperhidrosis disorder

0 Actively Recruiting

Increased upper airway secretion

0 Actively Recruiting

Anticholinergic Syndrome

0 Actively Recruiting

Induction of anesthesia therapy

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Emphysema

4 Actively Recruiting

Phase 2, Not Applicable

Oral cavity

0 Actively Recruiting

peripheral muscarinic effects

0 Actively Recruiting

Reflex, Trigeminocardiac

0 Actively Recruiting

Drooling

0 Actively Recruiting

Neurological Conditions

1 Actively Recruiting

Not Applicable

Bronchitis, Chronic

0 Actively Recruiting

cardiac vagal inhibitory reflexes

0 Actively Recruiting

Peptic Ulcer

0 Actively Recruiting

Bodily secretions

0 Actively Recruiting

Cerebral Palsy

0 Actively Recruiting

Bevespi Aerosphere Reviews: What are patients saying about Bevespi Aerosphere?

Patient Review

9/13/2019

Bevespi Aerosphere for Bronchospasm Prevention with COPD

I was amazed at how quickly this treatment worked. My legs started growing back within two weeks!

Patient Review

8/29/2018

Bevespi Aerosphere for Bronchospasm Prevention with COPD

On the first day, I could breathe again! However, the second day brought on a congestive cough. Reducing the dosage helped it work better for me. This treatment really relaxes my breathing, but I've only been using it for a week so time will tell.

Patient Review

8/6/2018

Bevespi Aerosphere for Bronchospasm Prevention with COPD

I used Bevespi for a couple months, and while it was great at first, my health slowly started declining. I eventually realized that it was the Bevespi causing these issues, specifically the weakness and lack of energy. Formoterol is terrible, and I'll never touch anything with it again.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about bevespi aerosphere

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is BEVESPI AEROSPHERE a steroid?

"Bevespi Aerosphere is not used for asthma because it doesn't contain a steroid medication."

Answered by AI

What type of inhaler is Aerosphere?

"The Bevespi Aerosphere is a handheld canister that gives you a puff of your medicine as an inhaled mist. It is used in the treatment of chronic obstructive pulmonary disease (COPD)."

Answered by AI

What is Bevespi inhaler used for?

"BevESPI Atmosphere is a prescription medication used to manage chronic obstructive pulmonary disease (COPD). COPD encompasses chronic bronchitis, emphysema, or both. BevESPI Atmosphere is to be used as 2 inhalations, 2 times per day--once in the morning and once at night--so as to ease COPD symptoms and promote better breathing."

Answered by AI

What inhaler is comparable to Bevespi?

"Anoro ellipta and Bevespi Aerosphere are combinations of anticholinergics and long acting beta-adrenoceptor agonists (LABAs) used for the long-term, once-daily, maintenance treatment of airflow obstruction in ..."

Answered by AI

Clinical Trials for Bevespi Aerosphere

Image of Stanford University in Stanford, United States.

MoblO2 for Chronic Lung Diseases

18+

All Sexes

Stanford, CA

Many patients with chronic lung disease (e.g., chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD)) require supplemental oxygen (O2) at some point during their disease course. Practitioners prescribe O2 to patients with chronic lung disease in hopes of the following: 1) that it will limit desaturation events and combat breathlessness, thus preventing the frustratingly slow pace and numerous rest breaks patients are forced to adopt while doing even simple tasks; 2) that it will allow patients to be more active physically (perhaps increase their ability to exercise) and socially (perhaps leave the home more often); 3) that it will stave off putative complications of hypoxemia (e.g., cognitive dysfunction, pulmonary hypertension) and 4) that it will improve health-related quality of life (HRQL). However, despite the rationale for O2, and prescribers' good intentions, patients generally view O2 with frustration and fear - it threatens their HRQL, which is already impaired by having a condition that imposes itself on every aspect of their lives. Nasal cannulas and delivery devices call unwanted attention to patients when they are out in public. O2 users feel stigmatized and are often viewed as "smokers who get what they deserve, even if they never smoked a day in their lives" - or as disabled, sick or even infectious. O2 steals patients' independence, forcing them to plan their lives around it. The anxiety that patients and their caregivers experience around running out of oxygen, or not getting enough, immobilizes them and restricts participation in activities outside of the home. O2 disrupts the home environment, adding stress, and creating a burden for patients' caregiver-loved-ones who are often saddled with the responsibility of ensuring adequate equipment and supply of O2, and O2 is a constant reminder to patients they are living with a condition that could shorten their lives. O2 delivery equipment is typically heavy, unwieldy and intimidating. Different recommendations (e.g., insurance companies use 88% as a cut-off for SpO2, while many practitioners focus on 90%) make it confusing for patients, which almost certainly affects adherence. O2-requiringpatients are starving for things that can make their lives easier. An auto-adjusting O2 delivery device - one that automatically delivers the correct amount of O2 to maintain blood oxygen at desired, pre-set levels - would alleviate the need for patients to constantly (incessantly for many) monitor their peripheral oxygen saturation (SpO2) and adjust O2flow to meet the demands as exertion levels vary . The MoblO2 device is a battery-operated, light-weight, closed-loop O2 delivery device that houses a regulator (which attaches to compressed gas O2 tanks) and adjusts O2 flow to meet a pre-set blood oxygen level. A pulse oximeter is worn on the ear and transmits via Bluetooth to the device, which adjusts an internal valve to control flow on a second-to-second basis. The user sets the dial to the highest flow of O2 needed to meet the demands of activities they might perform (up to 15 liters per minute), and the device adjusts flow, up to the pre-set level to maintain SpO2 at a preset level (e.g., \> 90%). To conserve O2 supply in the tank - and to avoid over-oxygenation (which could be problematic for a small percentage of patients with the most severe COPD) - the MoblO2 begins to limit O2 flow at a SpO2 of 93%. The device can be manually over-ridden by the user, and should the battery run out - or the device fail for some unforeseen reason - the default position is valve open, so the users receive whatever flow of oxygen has been set on the dial. Given the substantial burdens of O2 on patients and their families, the hassles patients describe with having to monitor their SpO2 and repeatedly adjust the flow of O2 to meet their needs, patients and experts around the world have called for improvements in O2 delivery equipment. The MoblO2 is just such a remarkable improvement and a giant step forward in helping to ease the burdens of O2 on patients who require it. The purpose of this study is to investigate the effects of the MoblO2 O2 delivery device on a range of outcomes, including physical activity, amount (liters) O2 use; maintenance of adequate SpO2 levels; patient reported outcomes including symptoms, HRQL and satisfaction with the MoblO2 O2 device.

Waitlist Available

Has No Placebo

Stanford University

Jeff Swigris, DO, MS

Minnesota Health Solutions